Bronchial artery embolization

Last updated
Bronchial artery embolization
Specialty Pulmonology, interventional radiology

Bronchial artery embolization is a treatment for hemoptysis, abbreviated as BAE. It is a kind of catheter intervention to control hemoptysis (airway bleeding) by embolizing the bronchial artery, which is a bleeding source. Embolic agents are particulate embolic material such as gelatin sponge or polyvinyl alcohol (PVA), and liquid embolic material such as NBCA, or metallic coils. [1]

Contents

Basic principle

It is said that hemoptysis is caused by the formation of anomalous anastomosis (bronchial artery-pulmonary artery shunt) between the bronchial artery and the pulmonary artery, and if the bronchial artery is embolized, hemorrhage will cease. [1] This is a fundamental concept of BAE. Traditionally, BAE was mostly performed as an emergency hemostatic procedure. Recently, it is often performed as an elective catheter treatment to prevent recurrence after massive hemoptysis, or control chronic repetitive hemoptysis. [2] Although it is termed bronchial artery embolization, various systemic arteries other than the bronchial artery (non-bronchial arteries) also form a shunt with the pulmonary artery and cause hemoptysis. Therefore, it is common to embolize such non-bronchial arteries, but the expression of bronchial artery embolization, BAE, rather than the universal expression "arterial embolization" is more common. [3] The therapeutic outcomes are improving due to the combined approach such as spreading the treatment target to non-bronchial arteries, development of 3D-CT angiography following the development of MDCT, the advancement of devices such as coils and micro-catheters, and the evolution of therapeutic strategies. BAE has become the gold standard for hemoptysis for its dramatic improvement. [4] [1] Although the hemostatic effect is greatly affected by the underlying disease, some high-volume centers report hemostatic rate of about 90.4% within one year of treatment, and 85.9% even in two years after treatment. [2] The occlusion of the blood vessels in the brain, heart, and kidneys, which are supplied by the so-called end arteries, can cause cerebral, myocardial, and renal infarctions. In BAE, both bronchial mucosal necrosis and pulmonary infarction seldom occur. [1] It is presumed that this is because the pulmonary circulation is dually controlled by the bronchial artery and the pulmonary artery; and even if the blood flow in the bronchial artery is lost, blood flow from the pulmonary artery is slightly maintained. [1]  In the case of non-bronchial arteries, it is empirically known that some collateral circulations also develop. [5] In addition, direct hemorrhage from the pulmonary artery is rare (less than 5%), which requires embolization of the pulmonary artery.[ citation needed ]

Treatment indications

BAE is effective for hemoptysis in most underlying diseases such as bronchiectasis, nontuberculous mycobacterial disease (NTM), cryptogenic hemoptysis, pulmonary aspergillosis, and pulmonary tuberculosis sequelae. [1] According to Ishikawa who reported long-term treatment results of BAE for 489 hemoptysis patients, each underlying disease's ratio is 34.0%, 23.5%, 18.4%, 13.3%, 6.8%, respectively. [2] Other diseases for which BAE is effective include lung abscess and pulmonary actinomycosis. [6]

As for lung cancer, hemoptysis is caused mostly by bleeding from the tumor itself, and not by the bronchial-pulmonary artery shunt mechanism; embolism of the feeding vessels for the tumor causes necrosis of the cancer which may evoke massive hemoptysis. In addition, subsequent chemotherapy and endovascular treatment cannot be performed if the route of anticancer drugs is permanently obstructed. Lung cancer needs a different strategy. Seki et al. reported the usefulness of endovascular treatment for lung cancer hemoptysis. [7] Kichang et al. reported BAE for hemoptysis in 84 lung cancer patients, and demonstrated that massive hemoptysis and cavity formation were significantly poor prognosis factors; re-hemoptysis rate was 23.8% in their follow-up period. [8]

Even though BAE is currently considered the gold standard treatment for hemoptysis, Ishikawa et al. [9] found that only 9065 patients (8.4%) out of  107389 patients hospitalized for hemoptysis between 2010 and 2018 in Japan were treated with BAE. According to Ishikawa basically, all patients with hemoptysis who are admitted to the hospital are eligible for BAE, and the reason why BAE has been performed only in such a small number of patients is that there are still few facilities that can perform BAE,

Besides, among the 660 hospitals that performed BAE, half of them (334 centers) experienced less than one case per year. [9] Centralization of hemoptysis treatment facilities will be necessary to increase the performance rate of BAE  and to improve the quality of BAE.

Treatment technique details

A catheter with a diameter of less than 2 mm is inserted at the base of the foot (femoral artery) or the artery in the wrist (radial artery). [2] The tip of the catheter is inserted into the orifice of the bronchial artery (normally smaller than 1 mm) or other non-bronchial hemoptysis-related arteries. Contrast agent is injected through the catheter, and when abnormal findings are observed, such as systemic–pulmonary shunts, proliferations of the capillary vessels, or extravasation of the contrast medium to the lung tissues, they were super selectively embolized using the 3 Fr microcatheter system. [5] A thinner microcatheter (about 0.8 mm) is passed through the catheter into the blood vessel, and then, embolic material is injected into the appropriate site. Thus, hemostasis is performed by ceasing or reducing the pressure applied to a bronchial (or non-bronchial)-pulmonary shunt (abnormal anastomosis). BAE is performed under local anesthesia, and the required time is about 1 hour to 3 hours. [2]

Effectiveness

In the past, BAE was mostly considered a palliative or a bridge therapy to surgical operation owing to the high rate of re-hemoptysis with BAE. But with the improvement in treatment strategy and devices, it is regarded as a permanent therapy for hemoptysis nowadays. [1] [4]

There are few facilities in which sophisticated BAE is feasible, and there are significant disparities between hospitals in the treatment quality and their experience. In most of the facilities, BAE is operated by interventional vascular radiology doctors, [10] but in recent years, specialized high volume centers where a trained pulmonologist performs BAE are emerging. [11] [2] It is particularly effective for cryptogenic hemoptysis. Ando, Masuda et al. reported in their article that the hemostatic rate is 97% at 20 months, [12] which is equivalent to the results of the article by Ishikawa. [2] Ando, Masuda et al. state that micro bronchial aneurysms are involved in 22.9% of cryptogenic hemoptysis [12]

For pulmonary aspergillosis, BAE was relatively less effective and was once thought to be contraindicated, but hemostatic rates have improved in recent years. Ando, Masuda et al. demonstrated that the re-hemoptysis rate was significantly higher in cases of disease progression. [11]

The hemostatic rate in each underlying disease by Ishikawa is shown below. [2] In this paper, both re-hemoptysis and death are defined as composite endpoints, and among these, only re-hemoptysis free rate is shown in the following table. It is originally a long-term performance data for 3 years; In the third year, the 95% confidence interval was too wide except for cryptogenic hemoptysis; hence, they are regarded as statistically unreliable figures. Therefore, the third year result is not posted here except for idiopathic hemoptysis. [2] The poorest hemostatic rate after 2 years was observed in nontuberculous mycobacterial disease (NTM). The result shown by Okuda, Masuda et al. was similar (73.8%). [13] It is considered to reflect the progressive nature of the disease.[ citation needed ]

Hemostatic rate by underground diseases [2]
Underground diseases   1 year2 year
Total90.4%85.9%
Bronchiectasis87.6%85.1%
NTM89.0%75.9%
Cryptogenic Hemoptysis97.8%97.8%
Pulmonary aspergillosis   86.4%82.1%
Tb sequelae   91.3%85.3%

Below are the treatment results summarized according to underlying diseases based on peer-reviewed papers published by Eishinkai Kishiwada Rehabilitation Hospital Hemoptysis and Pulmonary Circulation Center (EHPC), and The National Hospital Organization Tokyo Hospital Pulmonary Circulation and Hemoptysis Center (Tokyo Hp) ; the top two representatives of high-volume centers in Japan.

Cryptogenic Hemoptysis    [2] [12]
1year２year３yearCasesFollow-up period
Tokyo Hp97.0%353 years
EHPC97.8%97.8%97.8%905.7 years
NTM [2] [13]
1 year2 year3 yearCasesFollow-up period
Tokyo Hp79.1%73.8%63.3%435 years
EHPC89.0%75.9%N.A.1155.7 years
Aspergillosis [14]   [11]  
1 year2 year3 yearCasesFollow-up period
Tokyo Hp65.8%50.0%47.9%415 years
EHPC86.4%82.1%N.A.655.7 years

In cases of recurrence, re-BAE is possible to perform several times.

Furthermore, Takeda et al. showed that the 1, 2, 3, and 5-year hemostatic rates of bronchiectasis (without nontuberculous mycobacteriosis or pulmonary aspergillosis) were 91.3, 84.2, 81.5, and 78.9%, respectively. [15] This paper is valuable for its long-term results of 5 years.

Embolic material

These include polyvinyl alcohol (PVA), n-butyl-2-cyanoacrylate (NBCA), gelatin sponge, metallic coil, etc. [1] [4]

PVA

Woo et al. reported 406 cases of BAE long-term results, including 293 cases of PVA and 113 cases of NBCA. [16]

NBCA

This is a kind of medical instant adhesive. Generally, there are many complications such as non-target blood vessel embolization and adhesion of catheter and vessel wall. However, in the article by Woo et al., major complication rate was 0%. [16]

This kind has many advantages, such as low cost, instantaneous embolization, and very low recanalization rate since it does not depend on the patient's thrombus formation. It appears to be the best indication for traumatic bleeding control, particularly, in the peripheral bronchial aneurysms that the micro-catheter cannot access in BAE procedures, is a very good indication, and Mine, Hasebe et al. reported a technique called B-glue; NBCA combined with a balloon. [10]

Gelatin sponge (GS)

Gelatin sponge (GS) is a transient embolic material, and in most cases, it dissolves within one to two weeks, and blood flow resumes. For this reason, it is important for emergency hemostatic purposes such as palliative treatment until surgery, which was the former positioning of BAE. GS is not suitable for the prevention of recurrence after massive hemoptysis or elective BAE for chronic repetitive hemoptysis. Wada et al. demonstrated that hemostatic rate was 24% (median follow-up time was 15 months) in their retrospective analysis of BAE for 33 patients using GS. [17]

Metallic coil

There are three kinds of platinum vascular embolic coil. One is a detachable coil, which is expensive, but can be deployed repetitively until electric detach. This enables safest and fully controlled embolization. The second one is pushable coil, which is affordable, and allows for only one deployment. The third one is mechanical detachable coil; it has a moderate price range, and repetitive deployment is feasible. Ishikawa termed BAE with metallic coil as ssBACE, and published the world's largest number of cases of ssBACE long-term results in 2017. [2] As described below, there are no reports on spinal cord ischemia in ssBACE, [2] [11] which is considered the most serious complication of BAE. This is one of the strongest merit of ssBACE.[ citation needed ]

Despite a rumor that it cannot be re-treated if ssBACE is performed once, Ryuge demonstrated in their article on "the mechanism of re-hemoptysis" that the technical success rate in re-BAE was at least 97.7%. [18]

Re-hemoptysis mechanism

Ryuge classified the re-hemoptysis mechanism after ssBACE into four as shown below. They also demonstrated that for the improvement of the long-term results in ssBACE in the future, suppressing recanalization is necessary. [18]

Some readers misunderstand that 45.2% of the embolized coils recanalized. This, in fact, is the ratio of re-hemoptysis mechanism occurring in 9.6% cases in 1 year, and in 14.1% of those in 2 years. [18]

Recanalization was the main cause of re-hemoptysis, and the suppression of new hemoptysis-related vessels, which is the second cause, cannot be controlled by the BAE procedure itself. It was shown that suppression of the recanalization was the key to improvement in ssBACE result in future. [18]

Classification of the re-hemoptysis mechanism [18]
MechanismRatioExplanation
Recanalization45.2%Blood flow recurrence in the embolized area
New HRA38.5%Totally new hemoptysis-related artery
Bridging collateral14.7%Collateral from the proximal of the same artery
Conventional collateral1.7%Collateral from the different artery

Complications

Chest pain is the most common complication for who had undergone BAE, ranging from 24 to 91%. However, the symptom is temporary due to accidental embolisation of coronary artery supplying the heart. [19] In the past, paraplegia caused by spinal cord ischemia due to erroneous embolization of the anterior spinal artery was well known as a rare, but serious complication. [1] [20] Super selective BAE using microcatheter reduced the incidence of the spinal ischemia. [1]

However, according to Ishikawa et al., spinal cord infarction still occurs, with an incidence of 0.19% (16/8563). [9]

They also compared it between three embolic agents (GS, NBCA, Coil) and demonstrated that the incidence of spinal cord infarction was significantly lower in coils: 0.06% (1/1577) compared with GS 0.18% (12/6561) and NBCA 0.71% (3/425) (p=0,04).

Major complications reported by Ishikawa et al. are presented below. [2]

Mediastinal hematoma occurs by injury of hemoptysis-related vessel, mainly by wire, and can easily bail out by proximal coil embolization.[ citation needed ]

BAE complications (out of 489 cases) [2]
ComplicationsCasesIncidence
Mediastinal hematoma51.0%
Symptomatic cerebellar infarction20.4%
Aortic dissection10.2%
Symptomatic Cerebral infarction00%
Spinal ischemia00%
Death00%

Improvement in mortality and quality of life

The majority of research on BAE was the single-center retrospective observational studies. Descriptive epidemiological studies using French medical big data is precious in that aspect. [21] From the fall of 2020 to January 2021, a collaborative study led by the Yasunaga Laboratory of the University of Tokyo published two landmark papers using the Japanese medical database. [22] [9] One of them is a study by Ando et al. of the Department of Respiratory Medicine, University of Tokyo, which demonstrated for the first time in the world that early BAE (within three days after endotracheal intubation) significantly reduced in-hospital mortality in patients with severe hemoptysis on ventilators (30 days): 7.5% in the early BAE group vs. 16.8% in the non-early BAE group. (odds ratio, 0.45; 95% CI, 0.28-0.73; p = 0.001). [11]

Omachi et al. of the Hemoptysis and Pulmonary Circulation Center, Kishiwada Rehabilitation Hospital, demonstrated for the first time in the world that elective BAE with coils significantly improved the quality of life of hemoptysis patients(single-center prospective observational study).  In this study, both physical and mental QOL improved significantly after BAE, especially the latter. [23]

Related Research Articles

<span class="mw-page-title-main">Arteriovenous malformation</span> Vascular anomaly

An arteriovenous malformation (AVM) is an abnormal connection between arteries and veins, bypassing the capillary system. Usually congenital, this vascular anomaly is widely known because of its occurrence in the central nervous system, but can appear anywhere in the body. The symptoms of AVMs can range from none at all to intense pain or bleeding, and they can lead to other serious medical problems.

<span class="mw-page-title-main">Hemoptysis</span> Medical symptom consisting of bloody mucus from coughing

Hemoptysis or haemoptysis is the discharge of blood or blood-stained mucus through the mouth coming from the bronchi, larynx, trachea, or lungs. It does not necessarily involve coughing. In other words, it is the airway bleeding. This can occur with lung cancer, infections such as tuberculosis, bronchitis, or pneumonia, and certain cardiovascular conditions. Hemoptysis is considered massive at 300 mL. In such cases, there are always severe injuries. The primary danger comes from choking, rather than blood loss.

<span class="mw-page-title-main">Interventional radiology</span> Medical subspecialty

Interventional radiology (IR) is a medical specialty that performs various minimally-invasive procedures using medical imaging guidance, such as x-ray fluoroscopy, computed tomography, magnetic resonance imaging, or ultrasound. IR performs both diagnostic and therapeutic procedures through very small incisions or body orifices. Diagnostic IR procedures are those intended to help make a diagnosis or guide further medical treatment, and include image-guided biopsy of a tumor or injection of an imaging contrast agent into a hollow structure, such as a blood vessel or a duct. By contrast, therapeutic IR procedures provide direct treatment—they include catheter-based medicine delivery, medical device placement, and angioplasty of narrowed structures.

<span class="mw-page-title-main">Cerebral angiography</span> Angiography that produces images of blood vessels in and around the brain

Cerebral angiography is a form of angiography which provides images of blood vessels in and around the brain, thereby allowing detection of abnormalities such as arteriovenous malformations and aneurysms. It was pioneered in 1927 by the Portuguese neurologist Egas Moniz at the University of Lisbon, who also helped develop thorotrast for use in the procedure.

<span class="mw-page-title-main">Embolization</span> Passage and lodging of an embolus within the bloodstream

Embolization refers to the passage and lodging of an embolus within the bloodstream. It may be of natural origin (pathological), in which sense it is also called embolism, for example a pulmonary embolism; or it may be artificially induced (therapeutic), as a hemostatic treatment for bleeding or as a treatment for some types of cancer by deliberately blocking blood vessels to starve the tumor cells.

Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.

<span class="mw-page-title-main">Bronchial artery</span> Blood vessels supplying the lungs

In human anatomy, the bronchial arteries supply the lungs with oxygenated blood, and nutrition. Although there is much variation, there are usually two bronchial arteries that run to the left lung, and one to the right lung, and are a vital part of the respiratory system.

<span class="mw-page-title-main">Uterine artery embolization</span>

Uterine artery embolization is a procedure in which an interventional radiologist uses a catheter to deliver small particles that block the blood supply to the uterine body. The procedure is done for the treatment of uterine fibroids and adenomyosis. This minimally invasive procedure is commonly used in the treatment of uterine fibroids and is also called uterine fibroid embolization.

<span class="mw-page-title-main">Dural arteriovenous fistula</span> Medical condition

A dural arteriovenous fistula (DAVF) or malformation is an abnormal direct connection (fistula) between a meningeal artery and a meningeal vein or dural venous sinus.

Rasmussen aneurysm is a specific form of a pseudoaneurysm of the pulmonary artery, put simply a dilatation of a pulmonary artery branch, most commonly adjacent to or within a lung cavity as a complication of tuberculosis of the lung. Fritz Valdemar Rasmussen (1837–1877) originally described the condition in 1868. It is a rare complication of lung tuberculosis with cavitation, and occurs in 5–8% of cases based on autopsies.

<span class="mw-page-title-main">Chronic pulmonary aspergillosis</span> Fungal infection

Chronic pulmonary aspergillosis is a long-term fungal infection caused by members of the genus Aspergillus—most commonly Aspergillusfumigatus. The term describes several disease presentations with considerable overlap, ranging from an aspergilloma—a clump of Aspergillus mold in the lungs—through to a subacute, invasive form known as chronic necrotizing pulmonary aspergillosis which affects people whose immune system is weakened. Many people affected by chronic pulmonary aspergillosis have an underlying lung disease, most commonly tuberculosis, allergic bronchopulmonary aspergillosis, asthma, or lung cancer.

Percutaneous intentional extraluminal revascularization is a percutaneous technique used in interventional radiology for limb salvage in patients with lower limb ischemia due to long superficial femoral artery occlusions. This method is intended for those patients who make poor candidates for infrainguinal arterial bypass surgery. A guide wire is intentionally introduced in the subintimal space, after which balloon dilatation is performed to create a new lumen for the blood to flow through. The technique is not without complications but may serve as a "temporary bypass" to provide wound healing and limb salvage.

<span class="mw-page-title-main">Endovascular coiling</span>

Endovascular coiling is an endovascular treatment for intracranial aneurysms and bleeding throughout the body. The procedure reduces blood circulation to the aneurysm through the use of microsurgical detachable platinum wires, with the clinician inserting one or more into the aneurysm until it is determined that blood flow is no longer occurring within the space. It is one of two main treatments for cerebral aneurysms, the other being surgical clipping. Clipping is an alternative to stenting for bleeding.

Interventional neuroradiology (INR) also known as neurointerventional surgery (NIS), endovascular therapy (EVT), endovascular neurosurgery, and interventional neurology is a medical subspecialty of neurosurgery, neuroradiology, intervention radiology and neurology specializing in minimally invasive image-based technologies and procedures used in diagnosis and treatment of diseases of the head, neck, and spine.

Hepatic artery embolization, also known as trans-arterial embolization (TAE), is one of the several therapeutic methods to treat primary liver tumors or metastases to the liver. The embolization therapy can reduce the size of the tumor, and decrease the tumor's impact such its hormone production, effectively decreasing symptoms. The treatment was initially developed in the early 1970s. The several types of hepatic artery treatments are based on the observation that tumor cells get nearly all their nutrients from the hepatic artery, while the normal cells of the liver get about 70-80 percent of their nutrients and 50% their oxygen supply from the portal vein, and thus can survive with the hepatic artery effectively blocked. In practice, hepatic artery embolization occludes the blood flow to the tumors, achieving significant tumor shrinkage in over 80% of people. Shrinkage rates vary.

Interventional oncology is a subspecialty field of interventional radiology that deals with the diagnosis and treatment of cancer and cancer-related problems using targeted minimally invasive procedures performed under image guidance. Interventional oncology has developed to a separate pillar of modern oncology and it employs X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to help guide miniaturized instruments to allow targeted and precise treatment of solid tumours located in various organs of the human body, including but not limited to the liver, kidneys, lungs, and bones. Interventional oncology treatments are routinely carried out by interventional radiologists in appropriate settings and facilities.

<span class="mw-page-title-main">Prostatic artery embolization</span> Non-surgical technique for treatment of benign prostatic hypertrophy

Prostatic artery embolization is a non-surgical technique for treatment of benign prostatic hypertrophy (BPH).

Thoracic endometriosis is a rare form of endometriosis where endometrial-like tissue is found in the lung parenchyma and/or the pleura. It can be classified as either pulmonary, or pleural, respectively. Endometriosis is characterized by the presence of tissue similar to the lining of the uterus forming abnormal growths elsewhere in the body. Usually these growths are found in the pelvis, between the rectum and the uterus, the ligaments of the pelvis, the bladder, the ovaries, and the sigmoid colon. The cause is not known. The most common symptom of thoracic endometriosis is chest pain occurring right before or during menstruation. Diagnosis is based on clinical history and examination, augmented with X-ray, CT scan, and magnetic resonance imaging of the chest. Treatment options include surgery and hormones.

Transarterial bland embolization is a catheter-based tumor treatment of the liver. In this procedure, a variety of embolizing agents can be delivered through the tumor’s feeding artery in order to completely occlude the tumor’s blood supply. The anti-tumor effects are solely based on tumor ischemia and infarction of tumor tissue, as no chemotherapeutic agents are administered. The rationale for the use of bland embolization for hepatocellular carcinoma(HCC) and/or other hyper-vascular tumors is based on the fact that normal liver receives a dual blood supply from the hepatic artery (25%) and the portal vein (75%). As the tumor grows, it becomes increasingly dependent on the hepatic artery for blood supply. Once a tumor nodule reaches a diameter of 2 cm or more, most of the blood supply is derived from the hepatic artery. Therefore, bland embolization and transarterial chemoembolization (TACE) consist of the selective angiographic occlusion of the tumor arterial blood supply with a variety of embolizing agents, with or without the precedence of local chemotherapy infusion. The occlusion by embolic particles results in tumor hypoxia and necrosis, without affecting the normal hepatic parenchyma.

Anne Christine Roberts is an American interventional radiologist who is credited with the invention of the Roberts Uterine Catheter (RUC), a catheter designed to facilitate navigation through the uterine arteries and currently used widely for uterine artery embolization procedures. She also served as president of the Society of Interventional Radiology (SIR) (1996-1997) and was the second woman to become president of the society.

References

  1. 1 2 3 4 5 6 7 8 9 10 Panda, Ananya; Bhalla, Ashu Seith; Goyal, Ankur (2017-07-07). "Bronchial artery embolization in hemoptysis: a systematic review". Diagnostic and Interventional Radiology. 23 (4): 307–317. doi:10.5152/dir.2017.16454. PMC   5508955 . PMID   28703105.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 HIdeo, Ishikawa; Hara, Masahiko; Ryuge, Misaki; Takafuji, Jun; Youmoto, Mihoko; Akira, Masanori; Nagasaka, Yukio; Kabata, Daijiro; Yamamoto, Kouji; Shintani, Ayumi (February 2017). "Efficacy and safety of super selective bronchial artery coil embolisation for haemoptysis: a single-centre retrospective observational study". BMJ Open. 7 (2): e014805. doi:10.1136/bmjopen-2016-014805. ISSN   2044-6055. PMC   5318547 . PMID   28213604.
  3. ↑ Frood, Russell; Karthik, Shishir; Mirsadraee, Saeed; Clifton, Ian; Flood, Karen; McPherson, Simon J. (June 2020). "Bronchial Artery Embolisation for Massive Haemoptysis: Immediate and Long-Term Outcomes—A Retrospective Study". Pulmonary Therapy. 6 (1): 107–117. doi:10.1007/s41030-020-00112-x. ISSN   2364-1754. PMC   7229022 . PMID   32185642.
  4. 1 2 3 Olsen, Kathryn M.; Manouchehr-pour, Shawdi; Donnelly, Edwin F.; Henry, Travis S.; Berry, Mark F.; Boiselle, Phillip M.; Colletti, Patrick M.; Harrison, Nicholas E.; Kuzniewski, Christopher T.; Laroia, Archana T.; Maldonado, Fabien (May 2020). "ACR Appropriateness Criteria® Hemoptysis". Journal of the American College of Radiology. 17 (5): S148–S159. doi: 10.1016/j.jacr.2020.01.043 . PMID   32370959.
  5. 1 2 Yoon, Woong; Kim, Jae Kyu; Kim, Yun Hyun; Chung, Tae Woong; Kang, Heoung Keun (November 2002). "Bronchial and Nonbronchial Systemic Artery Embolization for Life-threatening Hemoptysis: A Comprehensive Review". RadioGraphics. 22 (6): 1395–1409. doi:10.1148/rg.226015180. ISSN   0271-5333. PMID   12432111.
  6. ↑ Suzuki, Manabu; Araki, Kyoko; Matsubayashi, Sachi; Kobayashi, Konomi; Morino, Eriko; Takasaki, Jin; Iikura, Motoyasu; Izumi, Shinyu; Takeda, Yuichiro (March 2019). "A case of recurrent hemoptysis caused by pulmonary actinomycosis diagnosed using transbronchial lung biopsy after bronchial artery embolism and a brief review of the literature". Annals of Translational Medicine. 7 (5): 108. doi: 10.21037/atm.2019.02.11 . ISSN   2305-5839. PMC   6462664 . PMID   31019958.
  7. ↑ Seki, Akihiko; Shimono, Chigusa (September 2017). "Transarterial chemoembolization for management of hemoptysis: initial experience in advanced primary lung cancer patients". Japanese Journal of Radiology. 35 (9): 495–504. doi:10.1007/s11604-017-0659-2. ISSN   1867-1071. PMID   28608003. S2CID   19991488.
  8. ↑ Han, Kichang; Yoon, Ki Woong; Kim, Jin Hyoung; Kim, Gyoung Min (March 2019). "Bronchial Artery Embolization for Hemoptysis in Primary Lung Cancer: A Retrospective Review of 84 Patients". Journal of Vascular and Interventional Radiology. 30 (3): 428–434. doi:10.1016/j.jvir.2018.08.022. PMID   30819488. S2CID   73468153.
  9. 1 2 3 4 Ishikawa, Hideo; Ohbe, Hiroyuki; Omachi, Naoki; Morita, Kojiro; Yasunaga, Hideo (2021-01-19). "Spinal Cord Infarction after Bronchial Artery Embolization for Hemoptysis: A Nationwide Observational Study in Japan". Radiology. 298 (3): 673–679. doi:10.1148/radiol.2021202500. ISSN   0033-8419. PMID   33464182. S2CID   231640899.
  10. 1 2 Mine, Takahiko; Matsumoto, Tomohiro; Hayashi, Toshihiko; Tomita, Kosuke; Masuda, Kimihiko; Kawashima, Masahiro; Sakamaki, Fumio; Hasebe, Terumitsu (2018-08-01). "A Stepwise Embolization Strategy for a Bronchial Arterial Aneurysm: Proximal Coil and Distal Glue with the Optional Use of a Microballoon Occlusion System". CardioVascular and Interventional Radiology. 41 (8): 1267–1273. doi:10.1007/s00270-018-1969-1. ISSN   1432-086X. PMID   29687263. S2CID   5039956.
  11. 1 2 3 4 5 Ando, Takahiro; Kawashima, Masahiro; Masuda, Kimihiko; Takeda, Keita; Okuda, Kenichi; Suzuki, Junko; Ohshima, Nobuharu; Horibe, Mitsuko; Tamura, Atsuhisa (2019-05-01). "Exacerbation of chronic pulmonary aspergillosis was associated with a high rebleeding rate after bronchial artery embolization". Respiratory Investigation. 57 (3): 260–267. doi:10.1016/j.resinv.2018.12.009. ISSN   2212-5345. PMID   30692051. S2CID   59342084.
  12. 1 2 3 Ohta, Ken; Akagawa, Shinobu; Nagai, Hideaki; Tamura, Atsuhisa; Matsui, Hirotoshi; Ohshima, Nobuharu; Suzuki, Junko; Okuda, Kenichi; Takeda, Keita (2017-11-01). "Clinical and Angiographic Characteristics of 35 Patients With Cryptogenic Hemoptysis". Chest. 152 (5): 1008–1014. doi:10.1016/j.chest.2017.05.007. ISSN   0012-3692. PMID   28526654. S2CID   3763317.
  13. 1 2 Okuda, Kenichi; Masuda, Kimihiko; Kawashima, Masahiro; Ando, Takahiro; Koyama, Kazuya; Ohshima, Nobuharu; Tamura, Atsuhisa; Nagai, Hideaki; Akagawa, Shinobu (2016-01-01). "Bronchial artery embolization to control hemoptysis in patients with Mycobacterium avium complex". Respiratory Investigation. 54 (1): 50–58. doi:10.1016/j.resinv.2015.08.004. ISSN   2212-5345. PMID   26718145.
  14. ↑ Ishikawa, Hideo; Hara, Masahiko; Ryuge, Misaki; Takafuji, Jun; Youmoto, Mihoko; Akira, Masanori; Nagasaka, Yukio; Kabata, Daijiro; Yamamoto, Kouji (February 17, 2017). "Efficacy and safety of super selective bronchial artery coil embolisation for haemoptysis: a single-centre retrospective observational study". BMJ Open. 7 (2): e014805. doi:10.1136/bmjopen-2016-014805. ISSN   2044-6055. PMC   5318547 . PMID   28213604.
  15. ↑ Takeda, Keita; Kawashima, Masahiro; Masuda, Kimihiko; Kimura, Yuya; Yamamoto, Shota; Enomoto, Yu; Igei, Hiroshi; Ando, Takahiro; Narumoto, Osamu; Morio, Yoshiteru; Matsui, Hirotoshi (2020). "Long-Term Outcomes of Bronchial Artery Embolization for Patients with Non-Mycobacterial Non-Fungal Infection Bronchiectasis". Respiration. 99 (11): 961–969. doi:10.1159/000511132. ISSN   0025-7931. PMID   33264771. S2CID   227259320.
  16. 1 2 Woo, Sungmin; Yoon, Chang Jin; Chung, Jin Wook; Kang, Sung-Gwon; Jae, Hwan Jun; Kim, Hyo-Cheol; Seong, Nak Jong; Kim, Young-Joo; Woo, Young-Nam (November 2013). "Bronchial Artery Embolization to Control Hemoptysis: Comparison of N -Butyl-2-Cyanoacrylate and Polyvinyl Alcohol Particles". Radiology. 269 (2): 594–602. doi: 10.1148/radiol.13130046 . ISSN   0033-8419. PMID   23801773.
  17. ↑ Wada, Noriaki; Furuya, Akio; Ike, Toshihiro; Kasai, Naofumi; Takata, Shohei; Tao, Yoshiaki; Asayama, Yoshiki (2019). "Clinical Features, Outcomes, and Predictors of Recurrence in Patients Treated with Bronchial Arterial Embolization Using a Gelatin Sponge to Control Hemoptysis". Interventional Radiology. 4 (3): 37–42. doi: 10.22575/interventionalradiology.2019-0002 . ISSN   2432-0935.
  18. 1 2 3 4 5 Ryuge, Misaki; Hara, Masahiko; Hiroe, Takanori; Omachi, Naoki; Minomo, Shojiro; Kitaguchi, Kazushi; Youmoto, Mihoko; Asakura, Norihiro; Sakata, Yasushi (2019-02-01). "Mechanisms of recurrent haemoptysis after super-selective bronchial artery coil embolisation: a single-centre retrospective observational study". European Radiology. 29 (2): 707–715. doi:10.1007/s00330-018-5637-2. ISSN   1432-1084. PMC   6302874 . PMID   30054792.
  19. ↑ Woong, Y; Kim, KF (1 November 2002). "Bronchial and Nonbronchial Systemic Artery Embolization for Lifethreatening Hemoptysis: A Comprehensive Review". Radiographics. 22 (6): 1395–1409. doi:10.1148/rg.226015180. PMID   12432111.
  20. ↑ Padgett, Max; Abi-Jaoudeh, Nadine; Benn, Bryan S.; Rahimian, Ramin; Nelson, Kari (June 2019). "Anterior Cord Syndrome after Embolization for Malignant Hemoptysis". Seminars in Interventional Radiology. 36 (2): 111–116. doi:10.1055/s-0039-1688424. ISSN   0739-9529. PMC   6531023 . PMID   31123382.
  21. ↑ Abdulmalak, Caroline; Cottenet, Jonathan; Beltramo, Guillaume; Georges, Marjolaine; Camus, Philippe; Bonniaud, Philippe; Quantin, Catherine (August 2015). "Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database". European Respiratory Journal. 46 (2): 503–511. doi: 10.1183/09031936.00218214 . ISSN   0903-1936. PMID   26022949.
  22. ↑ Ando, Takahiro; Kawashima, Masahiro; Jo, Taisuke; Masuda, Kimihiko; Yamauchi, Yasuhiro; Tanaka, Goh; Kage, Hidenori; Suzukawa, Maho; Nagai, Hideaki; Matsui, Hiroki; Fushimi, Kiyohide (October 2020). "Early Arterial Embolization and Mortality in Mechanically Ventilated Patients With Hemoptysis: A Nationwide Retrospective Cohort Study". Critical Care Medicine. 48 (10): 1480–1486. doi:10.1097/CCM.0000000000004513. ISSN   0090-3493. PMID   32931191. S2CID   221671429.
  23. ↑ Omachi, Naoki; Ishikawa, Hideo; Hara, Masahiko; Nishihara, Takashi; Yamaguchi, Yu; Yamamoto, Yumiko; Youmoto, Mihoko; Hattori, Tomoaki; Kitaguchi, Kazushi; Yamamoto, Shota; Kawaguchi, Tomoya (2021-01-06). "The impact of bronchial artery embolisation on the quality of life of patients with haemoptysis: a prospective observational study". European Radiology. 31 (7): 5351–5360. doi: 10.1007/s00330-020-07533-x . ISSN   0938-7994. PMC   8213576 . PMID   33409794.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.